Published in Cancer Weekly, September 26th, 2006
"Integrin alpha(v)beta(3) has been implicated in multiple aspects of tumor progression and metastasis. Many tumors have high expression of alpha(v)beta(3) that correlates with tumor progression. Therefore, alpha(v)beta(3) receptor is an excellent target for drug design and delivery," researchers in the United States reported.
"We have discovered a series of novel alpha(v)beta(3) antagonists utilizing common feature pharmacophore models," explained R. Dayam and colleagues, Stanford University. "Upon validation using a database of known...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.